Crescent Biopharma, Inc.
CBIO
$14.47
-$0.23-1.57%
NASDAQ
| 06/30/2025 | 03/31/2025 | ||||
|---|---|---|---|---|---|
| Net Income | -21.79M | -15.15M | |||
| Total Depreciation and Amortization | 2.00K | -- | |||
| Total Amortization of Deferred Charges | -- | -- | |||
| Total Other Non-Cash Items | 7.55M | 1.23M | |||
| Change in Net Operating Assets | -2.16M | 3.07M | |||
| Cash from Operations | -16.40M | -10.85M | |||
| Capital Expenditure | -140.00K | -- | |||
| Sale of Property, Plant, and Equipment | -- | -- | |||
| Cash Acquisitions | -- | -- | |||
| Divestitures | -- | -- | |||
| Other Investing Activities | -- | -- | |||
| Cash from Investing | -140.00K | -- | |||
| Total Debt Issued | -- | -- | |||
| Total Debt Repaid | -- | -- | |||
| Issuance of Common Stock | 144.28M | 5.00K | |||
| Repurchase of Common Stock | -177.00K | -- | |||
| Issuance of Preferred Stock | -- | -- | |||
| Repurchase of Preferred Stock | -- | -- | |||
| Total Dividends Paid | -- | -- | |||
| Other Financing Activities | 2.76M | -1.49M | |||
| Cash from Financing | 146.86M | -1.49M | |||
| Foreign Exchange rate Adjustments | -- | -- | |||
| Miscellaneous Cash Flow Adjustments | -- | -- | |||
| Net Change in Cash | 130.32M | -12.34M | |||